CStone Pharmaceuticals (HKSE:02616) Debt-to-Equity : N/A (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Debt-to-Equity?

CStone Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$0.0 Mil. CStone Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$0.0 Mil. CStone Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was HK$0.0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CStone Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

HKSE:02616' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.14 Max: 0.8
Current: 0.8

During the past 8 years, the highest Debt-to-Equity Ratio of CStone Pharmaceuticals was 0.80. The lowest was 0.00. And the median was 0.14.

HKSE:02616's Debt-to-Equity is ranked worse than
83.47% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:02616: 0.80

CStone Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for CStone Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals Debt-to-Equity Chart

CStone Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.14

0.64

0.80

CStone Pharmaceuticals Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial									0.14	0.25	0.64	N/A	0.80

Competitive Comparison of CStone Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, CStone Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CStone Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CStone Pharmaceuticals's Debt-to-Equity falls into.

CStone Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CStone Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(152.378	+	245.154)	/	499.671
	=	0.80

CStone Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

CStone Pharmaceuticals (HKSE:02616) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CStone Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CStone Pharmaceuticals (HKSE:02616) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CSPHF:USA PH4:Germany

Address

218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123

Website

https://www.cstonepharma.com

CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines